AVXL Valuation
Anavex Life Sciences Corp
$
7.648
- Overview
- Forecast
- Valuation
AVXL Relative Valuation
AVXL's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, AVXL is overvalued; if below, it's undervalued.
Historical Valuation
No Data
Competitors Valuation Multiple
The average P/S ratio for AVXL's competitors is 116.36, providing a benchmark for relative valuation. Anavex Life Sciences Corp Corp (AVXL) exhibits a P/S ratio of 0.00, which is -100.00% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
People Also Watch
CRML
Critical Metals Corp
1.430
USD
-1.38%
MTAL
Metals Acquisition Ltd
9.970
USD
+0.40%
SWIM
Latham Group Inc
6.350
USD
+0.47%
MEG
Montrose Environmental Group Inc
19.935
USD
+1.66%
REPL
Replimune Group Inc
9.080
USD
+10.73%
AC
Associated Capital Group Inc
36.910
USD
-0.16%
ASTE
Astec Industries Inc
41.730
USD
+0.05%
CPF
Central Pacific Financial Corp
27.430
USD
+0.15%
MLR
Miller Industries Inc
46.450
USD
-0.47%
SHLS
Shoals Technologies Group Inc
4.790
USD
+1.48%
FAQ
Is Anavex Life Sciences Corp (AVXL) currently overvalued or undervalued?
Anavex Life Sciences Corp (AVXL) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of 145.38. The fair price of Anavex Life Sciences Corp (AVXL) is between to according to relative valuation methord.
What is Anavex Life Sciences Corp (AVXL) fair value?
How does AVXL's valuation metrics compare to the industry average?
What is the current P/B ratio for Anavex Life Sciences Corp (AVXL) as of May 20 2025?
What is the current FCF Yield for Anavex Life Sciences Corp (AVXL) as of May 20 2025?
What is the current Forward P/E ratio for Anavex Life Sciences Corp (AVXL) as of May 20 2025?